SCHEMBL10003039

SCHEMBL10003039

CCc1nc2c(cc1-c1ccccc1OC)c(OCC(F)(F)F)c(C(=O)O)n2C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 1/20 0.41
▸ GRIA2 P42262 1/20 0.40
▸ GRIA4 P48058 1/20 0.40
▸ ALPL P05186 2/20 0.38
▸ MAPT P10636 2/20 0.37
▸ THRB P10828 1/20 0.37
▸ ADORA3 P0DMS8 2/20 0.36
▸ ADORA1 P30542 2/20 0.36
▸ AKR1C3 P42330 1/20 0.36
▸ AKR1C2 P52895 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ HCRTR1 O43613 1/20 0.36
▸ HCRTR2 O43614 1/20 0.36
▸ LMNA P02545 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ UGCG Q16739 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10003811 0.90 SCN9A (0.40) SCN9AALPLMAPTADORA3ADORA1
SCHEMBL10003464 0.89 GRIA2 (0.39) SCN9AGRIA2GRIA4ALPLADORA3
SCHEMBL10003096 0.88 GRIA2 (0.35) SCN9AGRIA2GRIA4TSHRHSD17B10
SCHEMBL10003992 0.85 CNR2 (0.39) SCN9AMAPTAKR1C3AKR1C2KMT2A
SCHEMBL10003734 0.84 CYP1A2 (0.35) SCN9AMAPTADORA3HTTHSD17B10
SCHEMBL10003500 0.84 PTPN11 (0.41) SCN9AGRIA2GRIA4MAPTHSD17B10
SCHEMBL10002905 0.84 GRIA2 (0.38) SCN9AGRIA2GRIA4MAPTHTT
SCHEMBL10003394 0.84 GRIA2 (0.43) SCN9AGRIA2GRIA4MAPTTHRB
SCHEMBL10003113 0.83 CCKAR (0.37) SCN9AGRIA2GRIA4AKR1C3AKR1C2
SCHEMBL10003810 0.83 PIK3CA (0.45) SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH SCN9A 2788/4885GRIA2 3298/4885GRIA4 2962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback